Citations

Mayo Clinic

Showing 10 of 108572 citations.

Lurbinectedin in prostatic small cell and neuroendocrine carcinoma.
Meyer, Haley M, Sunkara, Rajitha, Beltran, Himisha , Rothmann, Emily , Armstrong, Andrew J. , Lipucci, Andrea, Stanton, Melissa, Armstrong, Andrew J , Courtney, Kevin D , Bryce, Alan H.

Journal of Clinical Oncology | January 29, 2024 | Volume: 42 | Issue: 4_suppl | Pages: 164-164

10.1200/jco.2024.42.4_suppl.164 Get It

164 Background: Lurbinectedin (L) is a novel inhibitor of oncogenic transcription that was granted accelerated approval by the Food and Drug Administration in June 2020 for the treatment of metastatic small cell lung cancer (SCLC) following disease progression on or after platinum-based chemotherapy (PBC). Prostatic small cell or neuroendocrine carcinoma (SC/NEPC) is a high-grade, invasive malignancy that accounts for < 1% of all prostate cancers. SC/NEPC is distinct from prostatic adenocarcinoma and behaves similar to SCLC. NCCN guidelines for SC/NEPC recommend following the SCLC treatment guidelines. Using these guidelines, L may be used as a second-line treatment in patients (pts) with SC/NEPC who progress on or after PBC. We aimed to characterize the baseline characteristics, clinical course and therapeutic outcomes of pts treated with L for SC/NEPC. Methods: After IRB approval, 18 cases were gathered from 4 academic oncology centers. Baseline patient data, prior treatments and L treatment outcomes, including best radiographic and serologic responses, overall survival (OS), progression-free survival (PFS) and treatment toxicity were assessed. The Kaplan-Meier method was used to calculate OS and PFS from the L start date. Clinical benefit rate (CBR) included pts with complete response (CR), partial response (PR) and stable disease (SD) on imaging. Results: At the time of first L dose, all had metastatic disease with 2-6 distinct sites of metastases, most commonly bone (14/18, 77.8%), lymph nodes (14/18, 77.8%) and liver (13/18, 72.2%); median age was 63.5 (Range: 53-84); 11 pts (61.1%) had an ECOG 0-1; 4 pts (22.2%) had an ECOG of 2-3. The median total number of systemic therapies administered prior to L was 4 (Range: 2-7). All pts received PBC prior to L. The most common dose of L prescribed was 3.2 mg/m2 every 21 days (15/18, 83.3%). Androgen deprivation therapy was administered in conjunction with L in 9 pts (50%). The median number of cycles of L was 5 (Range: 1-10). L was discontinued due to toxicity in 1 patient (5.6%), disease progression in 10 pts (55.6%), transition to hospice in 2 pts (11.1%), 3 pts (16.7%) died while receiving treatment (not due to L toxicity), and 2 pts (11.1%) remained on L at the time of data reporting. The median OS and PFS from date of first L dose was 6.01 months (0.23 – 16.69) and 3.35 months (0.16 – 7.79), respectively. CBR was 9/16 (56.3%) with partial response in 5 pts (31.3%), stable disease in 4 pts (25%), and progressive disease in 7 pts (43.8%). Two pts did not have post-treatment imaging available to assess response. There were no hospitalizations for L treatment related adverse events (tRAE). The most common tRAE were grade I and II fatigue and anemia; 9 pts (50%) experienced no tRAE. The only grade IV toxicity was neutropenia in 3 pts (16.7%). Conclusions: L is a well-tolerated and active treatment option for patients with SC/NEPC. Prospective studies are needed to determine the role of L in the treatment of SC/NEPC.
Comparative health-related quality of life (QoL) in metastatic castration-sensitive prostate cancer (mCSPC): A living systematic review.
Morales, Rodolfo Garza, Naqvi, Syed Arsalan Ahmed , Ayaz, Ahsan , Khakwani, Kaneez Zahra Rubab, Riaz, Zaryab Bin, Raina, Ammad, Ravi, Praful , Andrews, Jack R. , Orme, Jacob J. , Cobran, Ewan K. , Garza-Morales, Rodolfo , Childs, Daniel S. , Singh, Parminder Pal , Riaz, Irbaz Bin , Bryce, Alan H.

Journal of Clinical Oncology | January 29, 2024 | Volume: 42 | Issue: 4_suppl | Pages: 111-111

10.1200/jco.2024.42.4_suppl.111 Get It

111 Background: Comparative evidence of quality of life (QoL) outcomes regarding life-prolonging treatments for the management of first-line treatment of metastatic castration sensitive prostate cancer (mCSPC) is not known. Methods: This systematic review uses the living interactive evidence synthesis framework (PMID: 36862387). Phase III randomized controlled trials assessing contemporary systemic treatments in mCSPC were included. Small sample size adjusted standardized mean differences (SMD; Hedges’ g) with 95% confidence intervals (CI) were computed for global QoL at 3, 6, 12, and 24 mo. Positive SMD indicated better health-related QoL, with zero indicating a null effect. Mixed treatment comparisons were made using a network meta-analysis. P-scores were computed; a higher score indicated better QoL. Results: Of 10 clinical trials initially included, eight trials (15 references) reported QoL. At 3mo global QoL was improved with abiraterone (AAP)+ADT compared to D+ADT (SMD: 0.26; 95% CI: 0.13-0.39), enzalutamide (E)+ADT (0.18; 0.03-0.33), and ADT (0.14; 0.02-0.27). At 6mo, AAP+ADT significantly improved global QoL compared to D+ADT (0.74; 0.62-0.87), E+ADT (1.74; 1.56-1.92), and ADT (1.79; 1.65-1.93). D+ADT also improved global QoL at 6mo compared to ADT (1.05; 0.93-1.16) but not when compared to E+ADT. At 12mo, AAP+ADT improved global QoL compared to E+ADT (0.20; 0.05-0.34) and ADT (0.19; 0.07-0.31) but not compared to D+ADT (0.05; -0.07-0.17). D+ADT also improved global QoL at 12mo compared to ADT (0.14; 0.03-0.24) (Table). Global QoL has not been reported for ARASENS trial at this time. These results are available on the Living interactive website. Conclusions: The totality of evidence suggests improved global QoL with androgen-pathway inhibitors (API) doublet therapy. D+ADT may offer better QoL at longer 6 and 12 months of follow-up. QoL data for triplet therapy is still emerging and will be incorporated in the living review as soon as it becomes available. [Table: see text]
Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction–associated steatohepatitis
Francque, Sven , Hodge, Alexander , Boursier, Jérôme , Younes, Ziad , Rodriguez‐Araujo, Gerardo, Park, Grace S., Alkhouri, Naim , Francque, Sven M , Younes, Ziad H , Abdelmalek, Manal F.

Hepatology Communications | January 29, 2024 | Volume: 8 | Issue: 2 | Pages: No page available

10.1097/hc9.0000000000000335 | PMID 38285756 Get It

Background: Cenicriviroc (CVC) is a novel, orally administered antagonist of chemokine receptor types 2/5 that has demonstrated antifibrotic activity in a phase 2b study of patients with NASH. This phase 2, open-label, rollover study investigated the long-term safety and tolerability of CVC in patients with NASH and stage 0–4 liver fibrosis. Methods: Eligible patients who completed the phase 2 CENTAUR study or reached a predefined endpoint in the phase 3 AURORA study were rolled over and received open-label CVC 150 mg once daily. Safety assessments were conducted at the start of the study, and patients were seen in the clinic every 3 months until the study sponsor terminated CVC development. Safety endpoints included treatment-emergent adverse events (TEAEs), treatment-related TEAEs, adverse event severity, and clinical laboratory assessments. Results: A total of 167 patients were enrolled, with a median treatment duration of 33.6 months. Before study termination, 36 patients (21.6%) prematurely discontinued the study. Treatment-related TEAEs were reported in 28 patients (16.8%). The most common treatment-related TEAEs were 4 cases of diarrhea (2.4%) and 2 cases each (1.2%) of abdominal pain, nausea, alanine aminotransferase increased, aspartate aminotransferase increased, hypertriglyceridemia, myalgia, pruritus, and rash. The majority of these treatment-related events were mild in intensity, and none were life-threatening. There were no clinically meaningful changes in hepatic function, chemistry, or liver parameters from baseline to the end of the study. Conclusions: In this rollover study, CVC 150 mg once daily was well tolerated in patients with NASH and stage 0–4 liver fibrosis. No new safety signals were reported, and these data further support the safety and tolerability of CVC.
A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002.
Aranha, Olivia , Javle, Milind , Rosales, Minori Koshiji, Hu, Zishuo Ian , Faridi, Amir A., Paulson, Scott, Richards, Donald , Höchster, Howard S. , Cosgrove, David , Azad, Nilofer S. , Brown‐Glaberman, Ursa, Cline, Vivian Jean M., Shumway, Nathan M., Tejani, Mohamedtaki Abdulaziz, Nallapareddy, Sujatha, Kelley, Robin Kate , Şahin, İlyas , Borad, Mitesh J. , Goyal, Lipika

Journal of Clinical Oncology | January 29, 2024 | Volume: 42 | Issue: 3_suppl | Pages: TPS587-TPS587

10.1200/jco.2024.42.3_suppl.tps587 Get It

TPS587 Background: Biliary tract cancer (BTC) is characterized by generally poor prognoses with limited treatment options. Systemic chemotherapy usually begins with gemcitabine, platinum agents, and a checkpoint inhibitor followed by 5-FU and oxaliplatin, irinotecan or a taxane. Presently, there is no consensus second-line therapy for patients with BTC. The DLL/Notch signaling pathway has been described to be a major driver of cholangiocarcinogenesis and VEGF-A overexpression has been reported in BTC tumors, correlating with stage, metastasis, and prognosis of the disease. CTX-009 is a recombinant bispecific antibody that binds both delta-like ligand-4 (DLL4) and vascular endothelial growth factor A (VEGF-A). The antibody simultaneously inhibits the DLL4-Notch 1 and VEGF A-VEGF receptor signaling pathways. Methods: COMPANION-002 (CTX-009 -002) is an open-label, randomized, controlled study in patients in second line advanced or metastatic BTC. To be eligible, patients must have radiologically documented progression after a prior gemcitabine and platinum containing chemotherapy regimen as first line therapy for locally advanced unresectable or metastatic disease. 150 patients will be randomized in a 2:1 ratio to receive either CTX-009 plus paclitaxel or paclitaxel alone. The stratification factors to be used at randomization include stage (locally advanced vs. metastatic), anatomic subsite of primary tumor (intrahepatic cholangiocarcinoma vs. other, i.e. extrahepatic cholangiocarcinoma, gallbladder, or ampullary), and Eastern Cooperative Oncology Group (ECOG) Performance status (0 vs. 1). Patients will be treated in 28-day cycles, with CTX-009 administered at 10 mg/kg IV on Day 1 and 15, and paclitaxel administered at 80 mg/m2 on days 1, 8, and 15. The patients randomized to paclitaxel arm can crossover after disease progression if selection criteria continue to be met. The primary objective of the study is to assess the efficacy of CTX-009 in combination with paclitaxel vs. paclitaxel alone, as measured by Overall Response Rate (ORR) assessed by an Independent Central Radiology (ICR) review. Key secondary objectives include overall survival, progression-free survival, and duration of response. Clinical trial information: 251040.
LoST: A Mental Health Dataset of Low Self-Esteem in Reddit Posts
Garg, Muskan, Goswami, Raxit, Sohn, Sunghwan , Gaur, Manas

2023 IEEE International Conference on Systems, Man, and Cybernetics (SMC) | January 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: 3854-3859

10.1109/smc53992.2023.10394671 | PMID 38524640 Get It

ASSOCIATION BETWEEN HISTOLOGICAL INDICES AND ULCERATIVE COLITIS ACTIVITY MEASURES AMONG PATIENTS IN THE HICKORY (ETROLIZUMAB) OPEN-LABEL INDUCTION (OLI) COHORT
Vogelsang, Harald, Feagan, B G, Pai, RK, Boruvka, Audrey, Oh, YS, Scherl, Alexis , Scalori, Astrid, Arrisi, Pablo, Tole, Swati, Rubin, DT, Peyrin‐Biroulet, Laurent

Zeitschrift für Gastroenterologie | January 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1712255 Get It

AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation.
Sonpavde, Guru , Kim, William Y. , Grivas, Petros , Chatta, Gurkamal , Reichert, Zachery R. , Bilen, Mehmet Asım , Srinivas, Sandy, Halabi, Susan , Burbano, Gabriela Perez , Halabi, Susan , Apolo, Andrea B , Ballman, Karla V. , Berg, Stephanie , Parikh, Rahul A , Teo, Min Yuen , Sweis, Randy F. , Geynisman, Daniel M. , Kim, Joseph W. , McGregor, Bradley A. , Morris, Michael J. , Rosenberg, Jonathan E

Journal of Clinical Oncology | January 29, 2024 | Volume: 42 | Issue: 4_suppl | Pages: LBA531-LBA531

10.1200/jco.2024.42.4_suppl.lba531 Get It

LBA531 Background: Muscle-invasive urothelial carcinoma (MIUC) is an aggressive disease with high relapse rates. Neoadjuvant platinum-based chemotherapy (NAC) is the standard of care in patients (pts) who are cisplatin (Cis)-eligible. However, many pts are Cis-ineligible or have persistent muscle-invasive disease after NAC and surgery. We evaluated pembrolizumab (Pembro) as adjuvant therapy in pts with high-risk MIUC following surgical resection. Methods: The AMBASSADOR study is an open-label, randomized, phase III trial that enrolled pts with histologically confirmed MIUC of the bladder, upper tract, or urethra who (1) had ≥ pT2 and/or pN+ or margins+ at surgery (radical cystectomy, nephrectomy, nephroureterectomy, or ureterectomy) following NAC or (2) ≥ pT3 and/or pN+ or margins+ at surgery without NAC and were either Cis-ineligible or declined adjuvant Cis-based therapy. Pts were registered ≥4 to 16 weeks after surgery and randomized 1:1 to receive Pembro 200 mg every 3 weeks for 1 year or observation (Obs). Randomization was stratified by pathologic stage, centrally tested PD-L1 status, and prior NAC. The dual primary endpoints were disease-free survival (DFS) and overall survival (OS) with a target sample size of 739 pts and required 387 DFS and 320 OS events for final analysis. Secondary objectives included evaluation of DFS and OS in PD-L1-positive and -negative pts and assessing safety. Here we present the interim DFS and OS results. Results: Between 09/2017 and 08/2021 a total of 702 pts were randomized prior to early closure due to US FDA approval of nivolumab for MIUC pts: 354 pts to Pembro and 348 pts to Obs; 13.0% vs 21.6% withdrew from study without event in the Pembro vs Obs arms, respectively. 74 pts (21%) in the Obs arm received an immune checkpoint inhibitor. Median follow-up was 22.3 months (mos) for DFS and 36.9 mos for OS. The DFS endpoint (based on 319 events needed for interim analysis) crossed the efficacy boundary. Median DFS was 29.0 months (95% confidence interval (CI) 21.8‒not evaluable (NE)) with Pembro and 14.0 months (95% CI 9.7‒20.20) with Obs (hazard ratio (HR) 0.69 [95% CI 0.55–0.87]; p=0.0013). At the interim analysis (n = 257 events), median OS was 50.9 months (95% CI 43.9‒NE) with Pembro and 55.8 months (95% CI 53.3‒NE) with Obs (HR 0.98 [95% CI 0.76–1.26]; p=0.88). Grade 3+ adverse events occurred in 48.4% and 31.8% of pts in the Pembro and Obs arms, respectively. Conclusions: Adjuvant Pembro demonstrated a statistically significant and clinically meaningful improvement in DFS vs Obs for high-risk MIUC pts after radical surgery. The OS endpoint may have been impacted by pts on the Obs arm receiving a checkpoint inhibitor. Pembro was tolerable with no new safety signals. These results support adjuvant Pembro as a new therapeutic option for pts with MIUC with high risk for recurrence. Additional follow-up is ongoing for the final DFS/OS, PD-L1 subgroups, and ctDNA analyses. Clinical trial information: NCT03244384 .
African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitis
Yazdanfar, Maryam , Zepeda, Joseph , Dean, Richard , Wu, Jialin , Goldberg, David S. , Lammert, Craig , Prenner, Stacey, Reddy, K. Rajender , Pratt, Daniel S. , Forman, Lisa , Assis, David N. , Lytvyak, Ellina , Carey, Elizabeth J. , Korzenik, Joshua R. , Karagozian, Raffi, Hameed, Bilal , Chandna, Shaun , Yu, Lei , Bowlus, Christopher L. , Korzenik, Joshua , Bowlus, Christopher L , Lytvyak, Ellina , Levy, Cynthia , Montaño‐Loza, Aldo J. , Gordon, Stuart C. , Ahn, Joseph , Schlansky, Barry L

Hepatology Communications | January 29, 2024 | Volume: 8 | Issue: 2 | Pages: No page available

10.1097/hc9.0000000000000366 | PMID 38285883 Get It

Background: The natural history of primary sclerosing cholangitis (PSC) among African Americans (AA) is not well understood. Methods: Transplant-free survival and hepatic decompensation–free survival were assessed using a retrospective research registry from 16 centers throughout North America. Patients with PSC alive without liver transplantation after 2008 were included. Diagnostic delay was defined from the first abnormal liver test to the first abnormal cholangiogram/liver biopsy. Socioeconomic status was imputed by the Zip code. Results: Among 850 patients, 661 (77.8%) were non-Hispanic Whites (NHWs), and 85 (10.0%) were AA. There were no significant differences by race in age at diagnosis, sex, or PSC type. Inflammatory bowel disease was more common in NHWs (75.8% vs. 51.8% p =0.0001). The baseline (median, IQR) Amsterdam-Oxford Model score was lower in NHWs (14.3, 13.4–15.2 vs. 15.1, 14.1–15.7, p =0.002), but Mayo risk score (0.03, −0.8 to 1.1 vs. 0.02, −0.7 to 1.0, p =0.83), Model for End-stage Liver Disease (5.9, 2.8–10.7 vs. 6.4, 2.6–10.4, p =0.95), and cirrhosis (27.4% vs. 27.1%, p =0.95) did not differ. Race was not associated with hepatic decompensation, and after adjusting for clinical variables, neither race nor socioeconomic status was associated with transplant-free survival. Variables independently associated with death/liver transplant (HR, 95% CI) included age at diagnosis (1.04, 1.02–1.06, p <0.0001), total bilirubin (1.06, 1.04–1.08, p <0.0001), and albumin (0.44, 0.33–0.61, p <0.0001). AA race did not affect the performance of prognostic models. Conclusions: AA patients with PSC have a lower rate of inflammatory bowel disease but similar progression to hepatic decompensation and liver transplant/death compared to NHWs.
Sex differences in trends and outcomes of acute myocardial infarction with mechanical complications in the United States
Rivera, Frederick Berro , Salva, Faye, Gonzales, Jacques Simon T., Whoy, Sung , Lumbang, Grace Nooriza O. , Planek, Isabel, Cruz, Mark Dela, Suboc, Tisha, Collado, F. , Cha, Sung Whoy , Lara-Breitinger, Kyla , Tang, Samantha , Kaur, Gurleen , Lara-Breitinger, Kyla M , Enriquez, Jonathan R. , Shah, Nishant , Santos Volgman, Annabelle

Expert Review of Cardiovascular Therapy | January 29, 2024 | Volume: 22 | Issue: 1-3 | Pages: 111-120

10.1080/14779072.2024.2311707 | PMID 38284754 Get It

Comparative analysis of Attention-based CNN andViT for processing ECG image data in joint fusion
Thakur, Arjun, Holmes, David R. , Fortuin, David, Banerjee, Imon , Banerjee, Imon , Agasthi, Pradyumna , Chao, Chieh‐Ju , Farina, Juan M. , Holmes, David R. , Arsanjani, Reza

No container title available | January 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3892330/v1 Get It

Abstract Percutaneous Coronary Intervention (PCI) is a widely utilized standard ofcare and efficacious intervention in the management of coronary artery disease,improving prognosis and symptoms for many patients. Prediction of post-PCIoutcomes contributes to effective patient management and quality improvementinitiatives in healthcare. Our study focuses on comparative performance analysisfor state-of-the-art vision transformer (ViT) and convolutional neural network(CNN) on multimodal data analysis in a joint fusion framework. We integrateimages of electrocardiogram (ECG) data and tabular electronic health records(EHR) to predict 3 clinically relevant post-PCI (6 months) endpoints - heart failure hospitalization, all-cause mortality, and ischemic stroke. To design a comparativemodel for ViT, we proposed a new joint fusion architecture that consistsof a convolutional neural network (CNN) with a convolutional block attentionmodule (CBAM). The learned representations are combined at an intermediatelayer followed by processing these representations using a fully connectedlayer. The proposed model demonstrates excellent performance with the highestAUROC scores of 0.849, 0.913, and 0.794 for predicting heart failure hospitalization,all-cause mortality, and stroke, respectively. Surpassing the baseline EHRmodel and ViT, the proposed CNN+CBAM fusion model showcases superiorpredictive capabilities for heart failure prediction.